SCHEMBL282157

SCHEMBL282157

Cc1cc2c(Cl)ncnc2cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP1 P22413 3/20 0.44
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
EGFR P00533 5/20 0.40
IRAK4 Q9NWZ3 2/20 0.40
SELE P16581 1/20 0.34
VCAM1 P19320 1/20 0.34
KDR P35968 4/20 0.34
FLT4 P35916 2/20 0.33
FGFR1 P11362 2/20 0.33
FLT1 P17948 2/20 0.33
FBP1 P09467 2/20 0.33
AURKA O14965 1/20 0.33
ERBB2 P04626 1/20 0.33
INSR P06213 1/20 0.33
PDGFRB P09619 1/20 0.33
CLK1 P49759 1/20 0.33
EPHB4 P54760 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29416616 0.84 PDE4A (0.47) ENPP1PDE4APDE4BPDE4CPDE4D
SCHEMBL1011889 0.84 PDE4A (0.47) ENPP1PDE4APDE4BPDE4CPDE4D
SCHEMBL2607973 0.84 ENPP1 (0.49) ENPP1PDE4APDE4BPDE4CPDE4D
SCHEMBL9975356 0.81 EGFR (0.42) EGFRIRAK4KDRFGFR1FLT1
SCHEMBL17030843 0.81 ENPP1 (0.46) ENPP1PDE4APDE4BPDE4CPDE4D
SCHEMBL833535 0.78 MAP4K4 (0.49) EGFRIRAK4
SCHEMBL2621720 0.78 PDE4A (0.41) ENPP1PDE4APDE4BPDE4CPDE4D
SCHEMBL2642415 0.78 PDE4A (0.41) ENPP1PDE4APDE4BPDE4CPDE4D
SCHEMBL15960738 0.78 ENPP1 (0.44) ENPP1PDE4APDE4BPDE4CPDE4D
SCHEMBL30562904 0.78 PDE4A (0.41) ENPP1PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11752153-B2 Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors SOUTHERN RESEARCH INSTITUTE (US) 2023-09-12 US disclosed
US-20230172932-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS SOUTHERN RESEARCH INSTITUTE (US) 2023-06-08 US disclosed
US-8957087-B2 Heterocyclic substituted acardite derivate and application thereof Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) 2015-02-17 US disclosed
EP-2428506-B1 HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF NANJING LUYESIKE PHARMACEUTICAL CO LTD (CN) 2014-03-05 EP disclosed
EP-2428506-A1 HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF Jiangsu Provincial Institute Of Materia Medica Co. (CN) 2012-03-14 EP disclosed
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) 2012-03-01 US disclosed
CN-101671301-A Heterocyclic substituent acardite derivate and application thereof JIANGSU PROVINCIAL INST OF MAT 2010-03-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 ENPP1 1684/4885PDE4A 2534/4885PDE4B 1922/4885
US-20230172932-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS TXN, TXNL1, TXN2 ENPP1 2704/4885PDE4A 2564/4885PDE4B 2505/4885
US-11752153-B2 Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors TXN, TXNL1, TXN2 ENPP1 2704/4885PDE4A 2564/4885PDE4B 2505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.